A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.

Clinical trial NCT01458197 · COMPLETED

Trial details

NCT number: NCT01458197
Sponsor: Kwang Dong Pharmaceutical co., ltd.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Overactive Bladder

Start date: 2011-09-01
Primary completion: 2012-08-01
Enrollment: 235

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.